StayCurrentMD · New insights into necrotizing enterocolitis: From laboratory observation to personalized prevention and treatment
Article1 min read·Published Jul 2018Older

New insights into necrotizing enterocolitis: From laboratory observation to personalized prevention and treatment

jpedsurg.org shows its articles on its own site.

Read the article on jpedsurg.org ↗

Article · Jul 2018 · 1 min read

In brief

In brief

This review examines necrotizing enterocolitis pathogenesis through the lens of exaggerated TLR4-mediated bacterial signaling in premature intestines. Novel TLR4 inhibitors and genetic screening approaches offer promise for personalized prevention and treatment strategies beyond current nonspecific interventions.

Written by the GCMD Library team from the article.

Abstract

Background/purpose

Necrotizing enterocolitis (NEC) is a devastating disease of prematurity that develops after feeding, often without warning, and results in diffuse intestinal necrosis leading to sepsis and death in many cases. The lack of improvement in overall survival is influenced by nonspecific diagnostic modalities as well as inexact and nonpersonalized treatment strategies.

Methods/Results

Recently, we and others have shown that NEC develops in response to exaggerated bacterial signaling in the premature intestine, as a consequence of elevated expression and activity of the bacterial receptor toll-like receptor 4 (TLR4), which is important for normal gut development. Breast milk is a powerful TLR4 inhibitor, while mutations in TLR4 genes lead to increased NEC risk in humans, providing proof-of-concept for its role in NEC. Recently, a drug discovery approach has revealed a novel class of TLR4 inhibitors which are being developed for personalized approaches to NEC treatment.

Conclusion

This review will highlight the current understanding of the role of bacterial signaling in NEC pathogenesis, and will describe advances in diagnosis, prevention and treatment of NEC that may hopefully improve survival for these most fragile patients.

Systematic Review

Level of Evidence: Level II.

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →